Literature DB >> 11934232

Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity.

João N Moreira1, Tatsuhiro Ishida, Rogério Gaspar, Theresa M Allen.   

Abstract

PURPOSE: Simple methods for the large-scale manufacture of ligand-targeted liposomes will be needed if clinical trials are to proceed. We tested a recently developed technology for inserting peptide ligands into preformed Stealth liposomes. Antagonist G-targeted liposomes (PLG) were prepared and loaded with doxorubicin and their cellular association and cytotoxicity were evaluated using the human small cell lung cancer H69 cell line.
METHODS: The hexapeptide antagonist G was covalently coupled via a thioether bond to the terminus of polyethylene glycol (PEG) in micelles formed from maleimide-derivatized poly(ethylene glycol) (Mr 2000) distearoylphosphatidylethanolamine followed by transfer into preformed liposomes during a one-step incubation. For cellular association, we used radiolabeled liposomes. Cytotoxicity was evaluated using the MTT in vitro proliferation assay.
RESULTS: The postinsertion approach to the formation of peptide-targeted liposomes led to the production of PLG bearing a maximum of approximately 0.3 microg antagonist G/micromol phospholipid. These liposomes had increased cellular association to H69 cells relative to nontargeted liposomes and, when loaded with doxorubicin, they resulted in similar levels of cytotoxicity to those obtained by conventional coupling techniques.
CONCLUSIONS: The postinsertion technique is a simple, effective means for the production of biologically active peptide-targeted liposomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934232     DOI: 10.1023/a:1014434732752

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

Review 2.  Chemical modifications of proteins: history and applications.

Authors:  G E Means; R E Feeney
Journal:  Bioconjug Chem       Date:  1990 Jan-Feb       Impact factor: 4.774

3.  Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time.

Authors:  P S Uster; T M Allen; B E Daniel; C J Mendez; M S Newman; G Z Zhu
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

4.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.

Authors:  D L Iden; T M Allen
Journal:  Biochim Biophys Acta       Date:  2001-08-06

5.  A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs.

Authors:  T Ishida; D L Iden; T M Allen
Journal:  FEBS Lett       Date:  1999-10-22       Impact factor: 4.124

6.  Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains.

Authors:  S Zalipsky; N Mullah; J A Harding; J Gittelman; L Guo; S A DeFrees
Journal:  Bioconjug Chem       Date:  1997 Mar-Apr       Impact factor: 4.774

7.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice.

Authors:  O Ishida; K Maruyama; K Sasaki; M Iwatsuru
Journal:  Int J Pharm       Date:  1999-11-10       Impact factor: 5.875

8.  Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.

Authors:  D W Northfelt; F J Martin; P Working; P A Volberding; J Russell; M Newman; M A Amantea; L D Kaplan
Journal:  J Clin Pharmacol       Date:  1996-01       Impact factor: 3.126

9.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

Authors:  D E Lopes de Menezes; L M Pilarski; T M Allen
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

10.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes.

Authors:  D C Litzinger; A M Buiting; N van Rooijen; L Huang
Journal:  Biochim Biophys Acta       Date:  1994-02-23
View more
  33 in total

1.  Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.

Authors:  Mohanambe Lingappa; Hong Song; Sarah Thompson; Frank Bruchertseifer; Alfred Morgenstern; George Sgouros
Journal:  Cancer Res       Date:  2010-07-22       Impact factor: 12.701

Review 2.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

3.  Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.

Authors:  Markus Gantert; Felicitas Lewrick; Joanna E Adrian; Jochen Rössler; Thomas Steenpass; Rolf Schubert; Regine Peschka-Süss
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

4.  Dual Functionalized 5-Fluorouracil Liposomes as Highly Efficient Nanomedicine for Glioblastoma Treatment as Assessed in an In Vitro Brain Tumor Model.

Authors:  Sushant Lakkadwala; Jagdish Singh
Journal:  J Pharm Sci       Date:  2018-07-25       Impact factor: 3.534

5.  Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.

Authors:  Yoshinori Kato; Wenlian Zhu; Marina V Backer; Christopher C Neoh; Sudath Hapuarachchige; Susanta K Sarkar; Joseph M Backer; Dmitri Artemov
Journal:  Pharm Res       Date:  2015-06-16       Impact factor: 4.200

6.  Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes.

Authors:  Shihong Li; Beth Goins; Brian A Hrycushko; William T Phillips; Ande Bao
Journal:  Mol Pharm       Date:  2012-08-23       Impact factor: 4.939

7.  The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma.

Authors:  Arun K Iyer; Yang Su; Jinjin Feng; Xiaoli Lan; Xiaodong Zhu; Yue Liu; Dongwei Gao; Youngho Seo; Henry F Vanbrocklin; V Courtney Broaddus; Bin Liu; Jiang He
Journal:  Biomaterials       Date:  2011-01-20       Impact factor: 12.479

Review 8.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

9.  Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

Authors:  Yingna He; Linhua Zhang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2010-09-20

10.  Programmable nanoparticle functionalization for in vivo targeting.

Authors:  Hua Pan; Jacob W Myerson; Lingzhi Hu; Jon N Marsh; Kirk Hou; Michael J Scott; John S Allen; Grace Hu; Susana San Roman; Gregory M Lanza; Robert D Schreiber; Paul H Schlesinger; Samuel A Wickline
Journal:  FASEB J       Date:  2012-10-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.